Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and pharmacokinetics of GSK3923868 inhalation powder in healthy participants and stable asthmatics; completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK3923868 (GSK3923868)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED | Results posted: 2024-02-20